KR102160462B1 - 뇌암의 치료 - Google Patents

뇌암의 치료 Download PDF

Info

Publication number
KR102160462B1
KR102160462B1 KR1020147029340A KR20147029340A KR102160462B1 KR 102160462 B1 KR102160462 B1 KR 102160462B1 KR 1020147029340 A KR1020147029340 A KR 1020147029340A KR 20147029340 A KR20147029340 A KR 20147029340A KR 102160462 B1 KR102160462 B1 KR 102160462B1
Authority
KR
South Korea
Prior art keywords
delete delete
solid dispersion
yloxy
methylphenyl
dihydrooxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147029340A
Other languages
English (en)
Korean (ko)
Other versions
KR20140139009A (ko
Inventor
파트리스 에이. 리
새넌 엘. 윈스키
케빈 코치
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102160462(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Priority to KR1020207027176A priority Critical patent/KR102317166B1/ko
Publication of KR20140139009A publication Critical patent/KR20140139009A/ko
Application granted granted Critical
Publication of KR102160462B1 publication Critical patent/KR102160462B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020147029340A 2012-03-23 2013-03-25 뇌암의 치료 Active KR102160462B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207027176A KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
US61/615,082 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027176A Division KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Publications (2)

Publication Number Publication Date
KR20140139009A KR20140139009A (ko) 2014-12-04
KR102160462B1 true KR102160462B1 (ko) 2020-09-28

Family

ID=48048296

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147029340A Active KR102160462B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020217033686A Active KR102490961B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020207027176A Active KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217033686A Active KR102490961B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020207027176A Active KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Country Status (30)

Country Link
US (3) US20150110780A1 (enExample)
EP (4) EP4252855A3 (enExample)
JP (6) JP2015514075A (enExample)
KR (3) KR102160462B1 (enExample)
CN (2) CN104203279B (enExample)
AU (4) AU2013234921A1 (enExample)
CA (1) CA2867723C (enExample)
CL (1) CL2014002497A1 (enExample)
CO (1) CO7071139A2 (enExample)
CY (2) CY1120204T1 (enExample)
DK (2) DK3400943T3 (enExample)
ES (2) ES2855142T3 (enExample)
HR (1) HRP20180659T1 (enExample)
HU (2) HUE053156T2 (enExample)
IL (3) IL234627B (enExample)
LT (1) LT2827900T (enExample)
MX (1) MX354024B (enExample)
MY (2) MY174883A (enExample)
NZ (4) NZ630843A (enExample)
PH (2) PH12021550360A1 (enExample)
PL (2) PL2827900T3 (enExample)
PT (2) PT3400943T (enExample)
RS (1) RS57140B1 (enExample)
RU (2) RU2672575C2 (enExample)
SG (1) SG11201405954YA (enExample)
SI (2) SI3400943T1 (enExample)
SM (1) SMT201800251T1 (enExample)
TR (1) TR201808450T4 (enExample)
UA (1) UA122044C2 (enExample)
WO (1) WO2013142875A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116875C2 (uk) 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
AU2012322039C1 (en) 2011-10-14 2021-04-29 Array Biopharma Inc. Solid dispersions of a Erb2 (HER2) inhibitor
PL2827900T3 (pl) 2012-03-23 2018-08-31 Array Biopharma, Inc. Dyspersja bezpostaciowego ciała stałego do zastosowania w leczeniu nowotworu mózgu
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
AU2018258663B2 (en) 2017-04-28 2022-08-04 Seagen Inc. Treatment of HER2 positive cancers
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
EP3773726B1 (en) * 2018-04-09 2024-06-05 Novocure GmbH Treating tumors with ttfields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AU2020419197B2 (en) * 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
EP1660090B1 (en) 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
US20100063074A1 (en) 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
HUE025507T2 (en) * 2008-03-18 2016-02-29 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
AU2012322039C1 (en) 2011-10-14 2021-04-29 Array Biopharma Inc. Solid dispersions of a Erb2 (HER2) inhibitor
UA116875C2 (uk) * 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
PL2827900T3 (pl) 2012-03-23 2018-08-31 Array Biopharma, Inc. Dyspersja bezpostaciowego ciała stałego do zastosowania w leczeniu nowotworu mózgu

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
American Association for Cancer Research Annual Meeting, 1-29쪽(2011.04.03.)*

Also Published As

Publication number Publication date
KR102317166B1 (ko) 2021-10-26
JP2022190126A (ja) 2022-12-22
EP2827900A1 (en) 2015-01-28
US20190255051A1 (en) 2019-08-22
IL234627B (en) 2018-10-31
PL2827900T3 (pl) 2018-08-31
EP4252855A3 (en) 2023-11-15
JP2021178820A (ja) 2021-11-18
MX354024B (es) 2018-02-08
NZ630843A (en) 2017-01-27
HUE037966T2 (hu) 2018-09-28
CN104203279B (zh) 2018-10-30
JP6898960B2 (ja) 2021-07-07
LT2827900T (lt) 2018-05-10
PT3400943T (pt) 2021-02-02
CA2867723C (en) 2022-11-08
PL3400943T3 (pl) 2021-06-14
TR201808450T4 (tr) 2018-07-23
CN109223791A (zh) 2019-01-18
NZ756264A (en) 2022-09-30
EP2827900B1 (en) 2018-03-21
ES2855142T3 (es) 2021-09-23
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
US20230190749A1 (en) 2023-06-22
RU2018138976A3 (enExample) 2022-04-08
KR20200115656A (ko) 2020-10-07
EP3400943B1 (en) 2020-12-02
DK2827900T3 (en) 2018-05-07
US20150110780A1 (en) 2015-04-23
JP7404485B2 (ja) 2023-12-25
JP2024019526A (ja) 2024-02-09
EP4252855A2 (en) 2023-10-04
JP2017141302A (ja) 2017-08-17
ES2673165T3 (es) 2018-06-20
CY1120204T1 (el) 2018-12-12
SI3400943T1 (sl) 2021-03-31
AU2019203618B2 (en) 2021-08-05
NZ741615A (en) 2019-10-25
PH12014502032A1 (en) 2014-11-24
KR20210131426A (ko) 2021-11-02
KR102490961B1 (ko) 2023-01-19
RU2014142700A (ru) 2016-05-20
KR20140139009A (ko) 2014-12-04
UA122044C2 (uk) 2020-09-10
AU2013234921A1 (en) 2014-10-02
AU2019203618A1 (en) 2019-06-13
RU2018138976A (ru) 2018-12-06
WO2013142875A1 (en) 2013-09-26
IL269205B (en) 2020-06-30
HRP20180659T1 (hr) 2018-06-01
AU2017272232C1 (en) 2019-08-15
IL269205A (en) 2019-11-28
MY202114A (en) 2024-04-04
PH12021550360A1 (en) 2023-04-03
NZ724544A (en) 2018-05-25
HUE053156T2 (hu) 2021-06-28
PT2827900T (pt) 2018-06-14
JP2019081792A (ja) 2019-05-30
JP2015514075A (ja) 2015-05-18
DK3400943T3 (da) 2021-02-08
MY174883A (en) 2020-05-20
SI2827900T1 (en) 2018-06-29
HK1206276A1 (en) 2016-01-08
AU2017272232A1 (en) 2018-01-04
CL2014002497A1 (es) 2014-11-14
CA2867723A1 (en) 2013-09-26
CY1123837T1 (el) 2022-05-27
RS57140B1 (sr) 2018-07-31
MX2014011437A (es) 2014-11-10
EP3842044A1 (en) 2021-06-30
IL261659A (en) 2018-10-31
RU2672575C2 (ru) 2018-11-16
AU2021261849A1 (en) 2021-12-02
SMT201800251T1 (it) 2018-07-17
CO7071139A2 (es) 2014-09-30
AU2017272232B2 (en) 2019-02-28
CN104203279A (zh) 2014-12-10
US11504370B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
KR102160462B1 (ko) 뇌암의 치료
HK40102024A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40055793A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406B (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK1206276B (en) Amorphous solid dispersion for use in the treatment of brain cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141020

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200619

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200921

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200922

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200923

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 6

End annual number: 6